These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 16052531)

  • 1. Effective inhibition of cell growth and invasion of melanoma by combined suppression of BRAF (V599E) and Skp2 with lentiviral RNAi.
    Sumimoto H; Hirata K; Yamagata S; Miyoshi H; Miyagishi M; Taira K; Kawakami Y
    Int J Cancer; 2006 Jan; 118(2):472-6. PubMed ID: 16052531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference.
    Sumimoto H; Miyagishi M; Miyoshi H; Yamagata S; Shimizu A; Taira K; Kawakami Y
    Oncogene; 2004 Aug; 23(36):6031-9. PubMed ID: 15208655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.
    Bhatt KV; Spofford LS; Aram G; McMullen M; Pumiglia K; Aplin AE
    Oncogene; 2005 May; 24(21):3459-71. PubMed ID: 15735667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
    Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
    Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
    Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
    Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells.
    Bhatt KV; Hu R; Spofford LS; Aplin AE
    Oncogene; 2007 Feb; 26(7):1056-66. PubMed ID: 16924241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models.
    Hoeflich KP; Gray DC; Eby MT; Tien JY; Wong L; Bower J; Gogineni A; Zha J; Cole MJ; Stern HM; Murray LJ; Davis DP; Seshagiri S
    Cancer Res; 2006 Jan; 66(2):999-1006. PubMed ID: 16424035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.
    Zuidervaart W; van Nieuwpoort F; Stark M; Dijkman R; Packer L; Borgstein AM; Pavey S; van der Velden P; Out C; Jager MJ; Hayward NK; Gruis NA
    Br J Cancer; 2005 Jun; 92(11):2032-8. PubMed ID: 15928660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on proliferation and melanogenesis by inhibition of mutant BRAF and expression of wild-type INK4A in melanoma cells.
    Rotolo S; Diotti R; Gordon RE; Qiao RF; Yao Z; Phelps RG; Dong J
    Int J Cancer; 2005 May; 115(1):164-9. PubMed ID: 15657897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A proliferative melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF mutation status.
    Zipser MC; Eichhoff OM; Widmer DS; Schlegel NC; Schoenewolf NL; Stuart D; Liu W; Gardner H; Smith PD; Nuciforo P; Dummer R; Hoek KS
    Pigment Cell Melanoma Res; 2011 Apr; 24(2):326-33. PubMed ID: 21176117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.
    Sumimoto H; Imabayashi F; Iwata T; Kawakami Y
    J Exp Med; 2006 Jul; 203(7):1651-6. PubMed ID: 16801397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF kinase gene V599E mutation in growing melanocytic lesions.
    Loewe R; Kittler H; Fischer G; Faé I; Wolff K; Petzelbauer P
    J Invest Dermatol; 2004 Oct; 123(4):733-6. PubMed ID: 15373778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
    Tanami H; Imoto I; Hirasawa A; Yuki Y; Sonoda I; Inoue J; Yasui K; Misawa-Furihata A; Kawakami Y; Inazawa J
    Oncogene; 2004 Nov; 23(54):8796-804. PubMed ID: 15467732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
    Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
    J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
    Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
    Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of B-RAF and N-RAS mutations in human melanoma.
    Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
    J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of V599E BRAF mutations in desmoplastic melanomas.
    Davison JM; Rosenbaum E; Barrett TL; Goldenberg D; Hoque MO; Sidransky D; Westra WH
    Cancer; 2005 Feb; 103(4):788-92. PubMed ID: 15641040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of NRAS and BRAF mutations in cutaneous melanoma.
    Rosso R; Romagosa Y; Kirsner RS
    J Invest Dermatol; 2009 Jun; 129(6):1318. PubMed ID: 19434085
    [No Abstract]   [Full Text] [Related]  

  • 19. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference.
    Sumimoto H; Yamagata S; Shimizu A; Miyoshi H; Mizuguchi H; Hayakawa T; Miyagishi M; Taira K; Kawakami Y
    Gene Ther; 2005 Jan; 12(1):95-100. PubMed ID: 15385954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells.
    Smith AG; Lim W; Pearen M; Muscat GE; Sturm RA
    Pigment Cell Melanoma Res; 2011 Jun; 24(3):551-63. PubMed ID: 21362156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.